Mikhail Blagosklonny, the Professor of Oncology and researcher at the Roswell Park Cancer Institute, explains how anti-ageing drugs can significantly improve the immunity and help in cancer treatments. He explained that Everolimus, a type of rapamycin analog, was found to be providing the desired results which include better immunity for older people and thus signaling for a dream of immortality. People believed that the aging is due to the random molecular damage which caused functional decline until recently. But, hyperfunction theory confirmed it as a continuation of growth. The new theory put forward the possibility of rapamycin being used to extend the healthy lifespan of a person along with the use of other rapalogs. Follow Mikhail on Google Scholar
The theory was initially put forward in 2008 and researchers were reluctant to accept it. But, now the rapamycin gets better acceptability, and Evirolimus is proved to be improving the immunity in aging people. Interestingly, Novartis, the famous drug manufacturer, is on its way to producing “Fountain of Youth’ Drug” which can delay the aging in elders and improve their health. According to Nir Barzilai, a famous researcher in anti-aging and colleague of Blagosklonny, the drug is used to target aging and slows down everything related to it, and it is a great turning point in the research of anti-aging. The TOR (Target of Rapamycin) was found to be producing starvation-like symptoms and other issues, and this led to the reinvention of the mTOR-centric model. However, the researchers feel that rapamycin would help the people to reach a post-aging age in the coming decades.
Blagosklonny is known for his researches in both cancer and aging. He is the man who framed the hyperfunction theory related to the aging which helped researchers to invent the anti-aging drugs. He believes by using anti-aging treatments people can prevent cancer and cure the disease better. Mikhail published around 300 papers, articles, reviews, and book chapters in various journals and books. He is also an associated editor for International Journal of Cancer, the American Journal of Pathology, and PLOS ONE. Blagosklonny dreams about the world without disease and that passion drives him to produce better results in his research. Visit classroomvoices.org to read more about Mikhail.
While coming to his education, Mikhail Blagosklonny completed his M.D. in Internal Medicine from First Pavlov State Medical University located in St. Petersburg. He continued his studies at the University and did his Ph.D. in Cardiology and Experimental Medicine. Blagosklonny started his career with New York Medical College as the associate professor in 2002. Later, he joined Ordway Research Institute as a senior scientist by keeping his vision of a disease-free world in mind. After few years with the Institute, Blagosklonny joined Roswell Park Cancer Institute as a researcher and Professor of Oncology. He also researches on Biogerontology and targeted cancer therapies which avoid healthy cells getting damaged during treatments.